Senseonics Holdings (SENS)
$0.40
0.02 (4.04%)
SENS Stock Quote Delayed 30 Minutes
Senseonics Can Move Higher, but Competitive Concerns Abound
While SENS stock features an exciting underlying business, it might have a vulnerability that investors may not be appreciating.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
211.84M
PE Ratio
-3.63
EPS
-0.11
Volume (Avg. Vol.)
1.98M
Day's Range
$0.40 - $0.42
52-Week Range
$0.40 - $1.05
Dividend & Yield
N/A (N/A)
SENS Stock Predictions, Articles, and Senseonics Holdings News
SENS Stock: 2 Big Reasons Senseonics Is Squeezing Higher
Today, two key catalysts are driving interest once again in Senseonics and SENS stock as retail investors focus on institutional buying.
Senseonics Could Go Higher, Especially if It Nabs FDA Approval
Senseonics looks interesting here, especially with possible FDA approval. SENS stock is worth about 24% more at over $4, or even $6-plus once its CGM rolls out.
Senseonics Financials Don’t Support Its Billion-Dollar-Plus Market Cap
Senseonics' revolutionary Eversense glucose monitor may be redefining diabetes treatment, but its current contribution doesn't justify SENS stock rich valuation.
Senseonics Is a Solid Recovery Play Poised to Unlock its Potential
SENS stock has rewarded patient investors well. However, this is only the beginning for the company as Eversense remains a gamechanger.
Senseonics Stock Might Actually Be Held Back By Its Meme Status
Senseonics has a long-term story that may be worth the wait. But right now, SENS stock is largely in the hands of retail investors who are looking to profit from a short squeeze.
Senseonics Still a Solid Bet on Potential $42 Billion Diabetic Market
With a growing diabetic market, Senseonics’ CGM could be a massive game-changer in a potential $42 billion market.
The Senseonics Price Will Start to Reflect the Key Advantage of Its Product
With markets in diabetes and wellness, Senseonics’ Eversense is an FDA-approved long-term implantable sensor that spells long-term growth for SENS stock.
Innovative Medical Technology Makes Senseonics a Long-Term Buy
Consider a niche-market investment in SENS stock as Senseonics' revenues outside the U.S. should impress even the toughest critics.
Wait For a Pullback Before Taking a Position In Senseonics
SENS stock has massive potential to establish itself as a major player in the growing CGM market, but is a bit too pricey at this point.
It’s Too Late to Ride Senseonics’ Reddit Wave
Even if you are interested in SENS stock for Senseonics' fundamentals, and not its short-squeeze potential, wait for a massive pullback.
Ignore Near-Sighted Apes and Own Senseonics
Most Reddit profiteering is short-term, but SENS stock has the kind of technology to make it the next big thing for other larger populations.
3 Pros and 3 Cons to Consider Before Joining the Senseonics Frenzy
While SENS stock is one of the more appealing risk-on trades on social media, you’ll want to assess its pros and cons carefully.
Senseonics Has Big Growth Potential From Groundbreaking Diabetes Treatment
Senseonics’ Eversense is the first long-term CGM. This advanced blood glucose monitoring tech will power SENS stock growth.
Senseonics Has Too Much Hope for Success Priced in Already
Reddit investors might be weakening, and Senseonics has to contend with a tough competitor, making SENS stock unattractive.
